Opus Genetics, Inc. (IRD)
NASDAQ: IRD · Real-Time Price · USD
5.00
-0.12 (-2.34%)
At close: Apr 28, 2026, 4:00 PM EDT
5.10
+0.10 (2.00%)
After-hours: Apr 28, 2026, 7:20 PM EDT
Opus Genetics Stock Forecast
Stock Price Forecast
The 10 analysts with 12-month price forecasts for Opus Genetics stock have an average target of 9.90, with a low estimate of 5.00 and a high estimate of 15. The average target predicts an increase of 98.00% from the current stock price of 5.00.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Opus Genetics stock from 10 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 5 | 6 | 6 | 6 | 5 |
| Buy | 2 | 2 | 2 | 2 | 4 | 5 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 7 | 8 | 8 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citizens | Citizens | Buy Initiates $12 | Buy | Initiates | $12 | +140.00% | Apr 28, 2026 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Initiates $15 | Buy | Initiates | $15 | +200.00% | Mar 30, 2026 |
| Oppenheimer | Oppenheimer | Buy Initiates $10 | Buy | Initiates | $10 | +100.00% | Mar 16, 2026 |
| Wedbush | Wedbush | Buy Maintains $8 → $10 | Buy | Maintains | $8 → $10 | +100.00% | Mar 12, 2026 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $9 → $11 | Strong Buy | Maintains | $9 → $11 | +120.00% | Mar 12, 2026 |
Financial Forecast
Revenue This Year
16.47M
from 14.20M
Increased by 16.03%
Revenue Next Year
19.27M
from 16.47M
Increased by 16.96%
EPS This Year
-0.53
from -0.80
EPS Next Year
-0.56
from -0.53
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 27.6M | 38.6M | ||||||
| Avg | 16.5M | 19.3M | ||||||
| Low | 7.8M | 7.8M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 94.5% | 134.2% | ||||||
| Avg | 16.0% | 17.0% | ||||||
| Low | -44.8% | -52.4% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -0.37 | -0.29 | ||||||
| Avg | -0.53 | -0.56 | ||||||
| Low | -0.71 | -0.73 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.